Buruli ulcer or Mycobacterium ulcerans infection

被引:4
作者
Abgueguen, P. [1 ]
Pichard, E. [1 ]
Aubry, J. [2 ]
机构
[1] CHU Angers, Serv Malad Infect & Trop, F-49933 Angers 9, France
[2] Univ Nantes, Inst Biol, INSERM, U892, F-44035 Nantes 1, France
来源
MEDECINE ET MALADIES INFECTIEUSES | 2010年 / 40卷 / 02期
关键词
Buruli ulcer; Mycobacterium ulcerans; Mycolactone; IN-VITRO; RISK-FACTORS; RIFAMPIN-STREPTOMYCIN; PHOSPHOLIPASE-C; IMMUNE-RESPONSE; AQUATIC INSECTS; TOXIC MACROLIDE; BOVIS BCG; PCR ASSAY; MYCOLACTONE;
D O I
10.1016/j.medmal.2009.08.021
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Buruli ulcer is a severe necrotizing cutaneous infection due to Mycobacterium ulcerans. The disease is currently expanding, especially in West Africa, and the WHO is supporting a vast research program to better understand the modes of transmission, to develop diagnostic methods, and to define specific treatment protocols. The disease transmission could be linked to environment and especially water striders. After M. ulcerans inoculation, cutaneous lesions appear, as broad painless ulcers, and thus ignored by patients. The production of mycolactone, a toxin, only virulence factor known at this time, is responsible for the cytotoxic effect on skin tissues. Complications may Occur, especially super infections and more rarely bone involvement responsible for osteomyelitis. The prognosis is usually functional with sometimes severe sequels, and skin and tendinous retraction as well as amputation are frequent. The diagnosis is usually made on PCR but this is difficult in developing countries, direct examination is not very reliable, and culture is long and difficult. The disease often remains ignored and undiagnosed, leading to evolved clinical presentations and sequels. The treatment is not defined yet. It is often surgical exeresis with skin graft, not always efficient. Antibiotic combination protocols are under evaluation. (C) 2009 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:60 / 69
页数:10
相关论文
共 95 条
[1]   Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M-ulcerans in vitro and in vivo [J].
Adusumilli, S ;
Mve-Obiang, A ;
Sparer, T ;
Meyers, W ;
Hayman, J ;
Small, PLC .
CELLULAR MICROBIOLOGY, 2005, 7 (09) :1295-1304
[2]  
Aguiar J, 1997, Med Trop (Mars), V57, P83
[3]   Buruli ulcer in Ghana: Results of a national case search [J].
Amofah, G ;
Bonsu, F ;
Tetteh, C ;
Okrah, J ;
Asamoa, K ;
Asiedu, K ;
Addy, J .
EMERGING INFECTIOUS DISEASES, 2002, 8 (02) :167-170
[4]  
[Anonymous], 2008, Wkly Epidemiol Rec, V83, P145
[5]  
[Anonymous], 1969, LANCET, V1, P111
[6]  
[Anonymous], 1971, T ROY SOC TROP MED H, V65, P763, DOI 10.1016/0035-9203(71)90090-3
[7]  
Bar W, 1998, TROP MED INT HEALTH, V3, P189
[8]   A stepwise approach to the laboratory diagnosis of Buruli ulcer disease [J].
Bretzel, G. ;
Siegmund, V. ;
Nitschke, J. ;
Herbinger, K. H. ;
Thompson, W. ;
Klutse, E. ;
Crofts, K. ;
Massavon, W. ;
Etuaful, S. ;
Thompson, R. ;
Asamoah-Opare, K. ;
Racz, P. ;
Vloten van, F. ;
Berberich, C. ;
Kruppa, T. ;
Ampadu, E. ;
Fleischer, B. ;
Adjei, O. .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2007, 12 (01) :89-96
[9]   Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)v [J].
Chauty, Annick ;
Ardant, Marie-Francoise ;
Adeye, Ambroise ;
Euverte, Helene ;
Guedenon, Augustin ;
Johnson, Christian ;
Aubry, Jacques ;
Nuermberger, Eric ;
Grosset, Jacques .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) :4029-4035
[10]   The use of IS2404 restriction fragment length polymorphisms suggests the diversity of Mycobacterium ulcerans from different geographical areas [J].
Chemlal, K ;
De Ridder, K ;
Fonteyne, PA ;
Meyers, WM ;
Swings, J ;
Portaels, E .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2001, 64 (5-6) :270-273